Madison, Wisconsin, U.S., September 30, 2026
Imbed Biosciences, a biotechnology company focused on advanced wound-care technologies, announced that its DualGuard™ Silver Gallium Matrix safety study has been registered on ClinicalTrials.gov. The study is designed to evaluate the safety and tolerability of the investigational wound-care matrix, which combines silver and gallium within a specialized matrix technology. The clinical study registration represents an important step in the development of DualGuard as Imbed Biosciences continues to advance technologies designed to address complex wounds and the challenges associated with wound healing. The program is particularly relevant to the growing need for innovative wound-care solutions that can help healthcare professionals manage wounds where infection risk and impaired healing present significant clinical challenges.
DualGuard Combines Silver and Gallium Technology
The DualGuard Silver Gallium Matrix represents an approach to wound management that incorporates two antimicrobial elements, silver and gallium, into a matrix designed for use in wound care. Silver has a long history of application in wound-care products because of its broad antimicrobial properties. Gallium, meanwhile, has attracted increasing scientific interest because of its potential interactions with biological processes and microbial iron metabolism. Combining these components within a wound-care matrix is intended to provide a differentiated approach for managing challenging wound environments. For patients with complex wounds, maintaining an appropriate wound environment can be an important component of care. Wounds can be affected by bacterial burden, inflammation, tissue damage, and other factors that may interfere with normal healing. Advanced wound-care technologies are therefore being developed to provide clinicians with additional tools for addressing these challenges. The registration of the DualGuard safety study on ClinicalTrials.gov provides greater visibility into the clinical development program and represents a transition toward evaluating the technology in a structured clinical setting. Safety and tolerability data generated through clinical investigation will be important in determining the next stages of development.
Clinical Study Focuses on Safety and Tolerability
The newly registered clinical study is focused primarily on evaluating the safety of DualGuard. Clinical safety studies are an important part of the development pathway for medical products because they help researchers identify potential adverse effects and determine how an investigational technology performs when used in patients. For Imbed Biosciences, the study is an important milestone as the company works to generate clinical evidence supporting the use of its silver-gallium matrix technology. Registration on ClinicalTrials.gov also reflects the increasing emphasis on transparency and public availability of information about clinical research. The study’s safety focus is particularly important for advanced wound-care products because wound treatments are applied directly to damaged tissue. Researchers must evaluate how the material interacts with the wound and surrounding tissue while monitoring participants for potential treatment-related complications. The resulting evidence can help guide subsequent clinical development and regulatory activities.
Advertisement
Advanced Wound Care Targets Unmet Clinical Needs
The development of DualGuard comes amid continued demand for innovative wound-care technologies. Chronic and complex wounds can require prolonged treatment and may place substantial burdens on patients, caregivers, and healthcare systems. Conditions such as diabetic foot ulcers, pressure injuries, burns, and other difficult-to-heal wounds can be associated with infection and delayed tissue repair. Imbed Biosciences has focused on developing advanced biomaterial technologies intended to support wound healing and improve clinical outcomes. The company’s work with DualGuard highlights the broader movement toward multifunctional wound-care products that combine material science with antimicrobial approaches.
The registration of the DualGuard Silver Gallium Matrix safety study therefore represents a meaningful development for the company and the broader wound-care and MedTech sectors. As clinical evaluation progresses, safety findings will help determine the future development pathway for the technology and its potential role in managing challenging wounds.
Source: Imbed Biosciences press release
